GC Biopharma has published a detailed review showcasing 30 years of research on its MAV/06 varicella vaccine, highlighting its safety and efficacy across multiple strains.

GC Biopharma's proprietary varicella vaccine strain, MAV/06, has received official recognition from the WHO, enhancing global vaccination efforts and supply security.

SK bioscience has submitted an IND to initiate a Phase 3 trial for its 2-dose varicella vaccine, aligning with global vaccination standards and addressing rising market demand.

GC Biopharma's varicella vaccine BARYCELA has secured marketing authorization in Vietnam, a key step in its Southeast Asian expansion strategy.